Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone
- Conditions
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 86
- Registration Number
- NCT01142518
A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
- Conditions
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 403
- Registration Number
- NCT01142492
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
- Conditions
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 231
- Registration Number
- NCT01142453
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT01126177
- Locations
- 🇬🇧
Southampton University General Hospital, Southampton, Hampshire, United Kingdom
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 42
- Registration Number
- NCT01075763
- Locations
- 🇮🇹
U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina, Catania, CT, Italy
Treatment Interruption of Natalizumab
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 175
- Registration Number
- NCT01071083
- Locations
- 🇪🇸
Research Site, Valencia, Spain
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 84
- Registration Number
- NCT01058005
- Locations
- 🇸🇪
Research Site, Molndal, Sweden
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2009-06-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 74
- Registration Number
- NCT00915577
Immunogenicity and Safety Study of Serum-Free Avonex
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Biogen
- Target Recruit Count
- 155
- Registration Number
- NCT00912860
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 136
- Registration Number
- NCT00599274
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
🇨🇦Coordinating Research Site, Halifax, Nova Scotia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.